Font Size: a A A
Keyword [crizotinib]
Result: 1 - 20 | Page: 1 of 4
1. Analysis Of The Efficacy And Safety Of Crizotinib In The Treatment Of ALK Gene Positive ANSCLC And The Detection Of ALK
2. Novel Approaches To Overcome HGF-mediated Resistance To Gefitinib In EGFR Mutant Non-small Cell Lung Cancer Cells
3. MiR-200c Regulates Changes Sensitivity Of Lung Cancer Cells To Crizotinib Through Regulation Of Epithelial-mesenchymal Transition
4. Crizotinib Activates Autophagy As A Cytoprotective Response In Human Lung Cancer Cells
5. Detecting HIF-1α MRNA And Analyzing Its Regulation Mechanism In Crizotinib-induced Apoptosis Of Lung Adenocarcinoma Cell Line H2228
6. The Role Of MTOR Signal Pathway In Crizotinib-induced Apoptosisi Of EML4-ALK Fusion Gene Positive Lung Adenocarcinoma Cell Line H2228
7. Building Of Xenograft Models For Non-small Cell Lung Cancer With Specific Gene Changes And Its Implication In Drug Therapy Evaluation
8. The Role Of Bim In Crizotinib-Induced Apoptosis Of EML4-ALK Fusion Gene Positive Lung Adenocarcinoma Cell Line H2228
9. The Study On The Effect Of ALK Inhibitor Crizotinib On Human Lymphocytes
10. Synthesis Of Non-small Cell Lung Cancer Drug Crizotinib
11. Role Of Stat3/Survivin Signaling Pathway In The EML4-ALK Positive Lung Adenocarcinoma Cell-Line H2228 Before And After Crizotinib Induced Resistance
12. Influence Of BIM Signaling Pathway In EML4-ALK Positive Lung Adenocarcinoma Cell-Line H2228 After Crizotinib Induced Resistance
13. ALK Variants, The Percentage Of ALK Positive Cells And Patients’ Treatment History On The Efficacy Of Crizotinib In ALK Rearranged NSCLC
14. Role Of HGF/c-Met Signaling Pathway In Crizotinib-Induced Of Different Lung Adenocarcinoma Cell Lines
15. Cyclosporine A Sensitize Human NSCLC Cells To Crizotinib Through Inhibition Of Ca2+/calcineurin/Erk Pathway
16. Clinical Analysis Of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
17. The Study Of Circulating MicroRNAs For Assistant Diagnosis Of ALK-rearrangement And Evaluation Of Crizotinib Therapy In Patients With Non-small Cell Lung Cancer
18. The Targeted Therapy Of Advanced Non-Small-Cell Lung Cancer Directed By Driver Genes
19. The Features Of ROS1 Positive NSCLC And Mutational Profiles With Crizotinib Resistance
20. Design,Synthesis And Biological Evaluation Of Novel ALK Inhibitors And The Construction Of Drug-like Libraries
  <<First  <Prev  Next>  Last>>  Jump to